Abstract | Cardiac fibroblasts deposit and maintain extracellular matrix during organogenesis and under physiological conditions. In the adult heart, activated cardiac fibroblasts also participate in the healing response after acute myocardial infarction and during chronic disease states characterized by augmented interstitial fibrosis and ventricular remodelling. However, delineation of the characteristics, plasticity, and origins of cardiac fibroblasts is an area of ongoing investigation and controversy. A set of genetic mouse models has been developed that specifically addresses the nature of these cells, in terms of both their origins and their response during cardiac disease and ventricular remodelling. As our understanding of cardiac fibroblasts becomes more defined and refined, so does the potential to develop new therapeutic strategies to control fibrosis and adverse ventricular remodelling.
Heart disease is the leading cause of mortality in the developed world. Coronary artery disease and its sequelae, including myocardial infarction (MI) and heart failure, are underlying causes of this lethality 1 . MI injury causes acute necrosis of cardiomyocytes in the affected area of the heart, with concomitant gener ation of a reparative fibrotic scar that, in the short term, prevents ventricular wall rupture. However, in longstanding heart failure, interstitial fibrosis accumu lates throughout the heart, leading to wall and septal stiffening and progressively worsening cardiac func tion 2 . Acute healing fibrosis after MI and longstanding progressive interstitial fibrosis during heart failure are primarily mediated by the activation and function of fibroblasts [3] [4] [5] . The cardiac fibroblast is a plentiful and definable cell type in the heart that expresses an array of extracellular matrix (ECM) proteins with type I collagen being the prototypical component. Disease activated fibroblasts have traditionally been referred to as myofibroblasts, in part because they express con tractile genes such as ACTA2, which encodes smooth muscle αactin (αSMA) [2] [3] [4] [5] . These activated fibroblasts also become more highly specialized in the generation and secretion of fibrillar collagens and matri cellular proteins [2] [3] [4] [5] . However, the functional properties of these cells have been largely documented in culture 6 ; con sequently, the details of how activated fibroblasts per form in vivo are still a topic of investigation. Further insights are also needed to determine whether the term myofibroblasts, which designates a contractile cell, is appropriate for fibroblasts in the diseased heart. Indeed, in the injured lung, noncontractile but activated fibroblasts (therefore not myofibroblasts) seem to be even more adept at ECM production and driving the fibrotic response 7 . Possibly owing to a lack of clear definitions for the cardiac fibroblast, many facets of fibroblast biology remain a topic of ongoing debates 4, 5 . The generation and characterization of genetic mouse models with fibroblastspecific or 'activated fibroblast'specific allele expression of Cre recombinase has allowed research ers to assess the role of cardiac fibroblasts in the mouse heart in more exact terms. In this Review, we discuss insights gained from the use of genetically engineered mice that allow a systematic evaluation of fibroblast identity 8 . The emerging picture suggests that, despite previous claims that activated fibroblasts transdiffer entiate from a wide array of unrelated cell types, the majority of injuryactivated, matrixproducing cells seem to expand from tissueresident fibroblasts that are already present in the myocardium and poised to respond [9] [10] [11] [12] . Given that the effectors involved in fibro blast activation have been reviewed previously 13, 14 , this article focuses primarily on current efforts to define the fibroblast population in the adult myocardium.
Resident cardiac fibroblasts
Initial studies first using morphology and flow cytometry have estimated that fibroblasts constitute between 27% and 50% of the total cells in mouse and rat ventricles, respectively [15] [16] [17] . Subsequently, a combination of histo logical and flow cytometric measurements were used to quantify fibroblasts. Although similar approaches had been used previously, refinements such as optimized tissue digestion, multiparametric analysis, and use of several cardiac fibroblastspecific mouse lines allowed robust calculation of the relative amounts of noncardio myocytes in the mouse and human hearts. In agreement with some previous findings, endothelial cells far out numbered the fibroblasts, which were less abundant than previously thought. Approximately 10% of the total cell number in the adult mouse myocardium is composed of resident adventitial and interstitial fibroblasts 18 . These resident cardiac fibroblasts (FIG. 1) are critical in the structural and mechanical maintenance of the heart. They coordinate the production and remodelling of the collagen network that is critical in ensuring correct conductivity and rhythmicity throughout the heart 2, 19, 20 . However, the presumed basal functions of fibroblasts in regulating the ECM and structural support of the heart are somewhat implied. Although embryonic loss of fibroblasts results in hearts with substantial reduction in type I and type III collagens, perinatal lethality precludes further investigation into additional roles of fibroblasts in the adult heart 21, 22 . Indeed, researchers have largely assumed that activated fibroblasts and/or myofibroblasts (FIG. 1) are the exclusive source of new collagen produc tion (such as type I, II, III, V, and VI collagens). However, this concept needs further mechanistic evaluation in vivo because other cell types can make and secrete particular types of collagens, including epithelial and endothelial cells [23] [24] [25] , skeletal muscle myotubes and fibres [26] [27] [28] , and cardiac myocytes 29, 30 . Therefore, to characterize all the roles of fibroblasts and activated fibroblasts in the heart, one would need to delete these cells or inactivate them at specific times. Researchers are beginning to under take these mechanistic approaches in disease models or after acute injury, but little has been done to understand the longterm basal role of tissueresident fibroblasts in the heart. Moreover, a thorough understanding of the regulation and function of activated fibroblasts or myofibroblasts after acute and chronic injury requires additional investigation
.
Another issue in attempting to elucidate the funda mental roles of cardiac fibroblasts is the somewhat non specific genetic tools that have previously been used to manipulate the activity or viability of these cells. For example, as discussed below, we have generated mice expressing a tamoxifeninducible Cre protein from the periostin (Postn gene) locus, which was used to induce a diphtheria toxin expression cassette to eliminate newly activated fibroblasts in the heart after MI injury 11 . This approach increased lethality in mice owing to inefficient collagen production and ventricular rupture 11 , empha sizing a critical role for activated fibroblasts in wound healing and scar formation.
Previous studies aimed at elucidating the baseline and disease effects of cardiac fibroblasts have been somewhat equivocal, because they relied on markers that were only partially specific to this presumed cell type 8 . For exam ple, discoidin domaincontaining receptor 2 (DDR2), fibroblastspecific protein 1 (FSP1, also called protein S100A4), Thy1 membrane glycoprotein (CD90), and vimentin, which have all been used in past studies puta tively to identify cardiac fibroblasts, are expressed by additional cell types in the heart. FSP1 or its promoter are expressed in many other cardiac cell types, with fibro blasts being in the minority 31 . Thy1 is expressed on most immune and endothelial cells 32 , and DDR2 and vimen tin are expressed in endothelial cells [33] [34] [35] . Herein lies the difficulty, as researchers had not reached a consensus definition of the fibroblast and its markers. Although still nascent, a consistent group of fibroblast markers is now emerging (FIG. 1) that has led to more consistency in defining this cell type and its function in the heart.
The latest data support the hypothesis that resident fibroblasts derived from the epicardium during embry onic development are the source of diseaserelevant activated fibroblasts or myofibroblasts in the adult heart. However, past studies suggested that cardiac fibroblasts originated from heterogeneous pools of cells that required transdifferentiation to achieve a fibroblast phenotype 36 . This latter concept disregards the presence of fibroblasts that already reside in the myocardium to mediate tissue remodelling and ECM production. Moreover, tissue resident fibroblasts are geometrically interspersed between cardio myocytes and are of the appropriate molecular pro gramme to allow rapid responsiveness after injury. The hypothesis that activ ated fibroblasts in the heart emerge from endothelial cells, pericytes, or immune cells would require that they first undergo molecular transdifferenti ation, a process that would lack rapid responsiveness and homogenous spatial coverage throughout the tissue.
Embryonic origins of cardiac fibroblasts
Progenitors of resident ventricular fibroblasts invade the mouse myocardium from the epicardium at embry onic (E) day 13.5, with molecularly distinct fibroblasts forming and interspersing throughout the ventricle by E17.5-E18.5 (REFS 21, 22, (37) (38) (39) (40) (FIG. 2) . This embry onic primary source of early epicardialderived fibro blasts is defined by expression of the marker genes Tcf21 (encoding transcription factor 21) 22 , Wt1 (Wilms tumour protein) 41, 42 , and Tbx18 (Tbox transcription factor TBX18) 43 . A second, minor developmental source of fibroblasts from the embryonic endothelium, identi fied by two groups using lineage tracing, was shown to constitute ~10-20% of the tissueresident fibroblasts in particular regions of the ventricular septum and right ventricle 10, 12 (FIG. 2) . Of note, these cells arise early during embryonic develop ment and are not generated by trans differentiation of mature endothelial cells. In addition to
Key points
• Cardiac fibroblasts are critical regulators of the basal structure of the heart and are also responsible for remodelling and fibrosis after injury • The identity and origin of disease-activated fibroblasts within the heart has been an ongoing debate • Tissue-resident fibroblasts of embryonic origin are interspersed throughout the adult mouse heart and comprise 10% of the total cell content • Recent studies indicate that tissue-resident fibroblasts differentiate into and constitute the majority of disease-activated fibroblasts and myofibroblasts after cardiac injury • Activated fibroblasts or myofibroblasts within the injured mouse heart are not appreciably derived from other non-tissue-resident fibroblast cell sources Tcf21, Wt1, and Tbx18 being markers of early embryonic fibroblasts of epicardial origin, plateletderived growth factor receptorα (Pdgfrα) 21 is also used to identify these cells, although only Tcf21 and Pdgfrα are expressed by resident mature fibroblasts of the adult heart 11, 21, 22, 44 .
Origins of activated cardiac fibroblasts
The common method of classifying activated fibro blasts is by detection of gene expression associated with matrix remodelling (encoding selected collagen types, collagenassembly proteins, and proteases) and/or those expressed by mesenchymal cells (encoding αSMA, fibronectin, and vimentin). However, the successful detection of these proteins and use to infer fibroblast identity or activation has had technical problems, leading to conclusions that were generally inconsist ent between laboratories. The diverse cell types that reportedly give rise to activated fibroblasts include endothelial cells 45, 46 , bonemarrowderived fibrocytes or immune cells [47] [48] [49] , mesenchymal stem/progenitor peri vascular cells 50, 51 , and adult epicardium 52, 53 (FIG. 2) . Some of these reports examined gene expression of cultured fibroblasts, in which the fibroblast was identified by adhesion to plastic or flow cytometry. Others have relied predominantly on immunohistochemistry with some form of lineage tracing. Surprisingly, few studies impli cated the resident fibroblast as a contributor to cardiac remodelling despite their fairly high abundance and obvi ous capacity to differentiate quickly into myofibroblasts without the need for transdifferentiation 16, 18 . Recent studies have demonstrated that the past conclusions regarding extracardiac sources and trans differentiation of endothelial cells as major contrib utors to fibrotic activities might not be quantitatively accur ate [10] [11] [12] (FIG. 2) . Multiple research groups, using bone marrow chimeras, parabiosis, and bonemarrow specific Cre lines, have reported either no or only modest contrib ution of bonemarrowderived cells to the injury responsive fibroblast population [10] [11] [12] . For example, lineage tracing of bonemarrowderived cells with LysMCre 54 or KitCre 55 showed no significant contribution of these lineages to the periostin expressing activated fibroblasts after MI injury 11 . Similar results were obtained using VavCre lineage tracing that demonstrated little contrib ution of the haematopoietic lineages to activated fibro blasts in the hearts of mice subjected to pressureoverload stress 10 . Further experi ments with bonemarrow chimer ism and parabiosis also showed minimal contribution of bonemarrow derived cells to the proliferating fibroblast population after pressure overload 12 .
Endothelialtomesenchymal transition has been proposed as a mechanism for fibroblast generation after MI and experimental diabetes mellitus on the basis of endothelial lineage tracing with Tie1Cre and Tie2Cre lines, but both of these studies also relied on FSP1 to iden tify fibroblasts 10, 31 (FIG. 2) . FSP1 is expressed in multiple cell types and is not a specific indicator of the fibroblast lineage in vivo, and the Tie1Cre and Tie2Cre lines are also expressed in immune cell lineages 10, 31 . . Mature, resident fibroblasts are interspersed throughout the myocardium and are proposed to maintain the extracellular matrix (ECM). They have a low level of proliferation and do not express smooth muscle α-actin (α-SMA) or periostin. After injury, a population of fibroblasts, often associated with inflammatory cell accumulation and cardiomyocyte death, rapidly proliferate and become activated to express many of the gene products shown. Later in the response, a smaller population of these activated fibroblasts further differentiate into presumed myofibroblasts, which express α-SMA and other genetic signatures shown. In the past, these myofibroblasts were reported to have increased ECM deposition and contractile capacities 89 , although in vivo contractile activity has been predominantly documented in skin myofibroblasts 90 . Myofibroblasts have also been shown to regress their activated gene-expression profile and morphology back to the more 'quiescent' and resident fibroblast state 11 . Ddr2, discoidin domain-containing receptor 2; NA, not available; Pdgfr-α, platelet-derived growth factor receptor-α; Tcf21; transcription factor 21. now show that endothelial cell conversion to fibroblasts after injury is very low. When Cdh5Cre, VEcadherin CreERT2, or Tie2Cre lineage tagging was used to label preexisting vascular endothelial cells, no fibroblasts were found to arise from this population after pres sure overload or MI injury [10] [11] [12] . Finally, using singlecell RNAseq, endothelial, smooth muscle, and haemato poietic lineage cells were found not to have a marker profile consistent with an activ ated fibroblast (defined by αSMA, periostin, and vimentin expression) 11 . Interestingly, Ubil and colleagues reported that fibroblasts in the mouse heart, as lineage traced using a Col1a2CreERT2 transgene, generated new endo thelial cells in the infarcted myocardium, indicating mesenchymal toendothelial transition 56 . However, Kanisicak and colleagues did not observe re expression of the endothelial cell marker CD31 after MI in two distinct cardiac fibroblast lineages, suggesting that tissue resident and activated fibroblasts do not gener ate CD31expressing endothelial cells 11 . After MI, smooth muscle cells and fibroblasts emerged from adult epi cardium 53, 57 , but after pressure overload by thoracic aortic constriction, few fibroblasts were found to origin ate from adult epi cardium 10, 12 . Data gener ated by indepen dent laboratories using lineage tracing and chimeric mouse models, therefore, suggest that injury activated, matrix producing transdifferentiated fibroblasts from sources such as endothelium, smooth muscle, bone marrow, and blood might be substantially less abundant than previously thought (FIG. 2) .
Injury-induced fibroblasts in the heart
Further studies have made a convincing case that tissue resident fibroblasts are the primary source of activated fibroblasts underlying tissue fibrosis and dis ease remodelling in the heart [10] [11] [12] 57 . First, Kanisicak and colleagues used a newly generated genetic tool in which a tamoxifenregulated mutated oestrogen receptorCre (mCrem) was inserted into the Postn locus. This pro cess generated a highly specific means of lineage tracing essentially all activated fibroblasts in the heart subjected to pressure overload, MI injury, or neuroendocrine stimulation, without labelling of other cell types 11 . Using the Postn mCrem allele together with a ROSA26 DTA cellular killing allele 58 , activated fibroblasts were shown to be required for healing and scar formation after MI injury in vivo 11 . The same study also showed that the tissue resident fibroblasts already in the heart were the over whelming source of activated fibroblasts after MI injury, pressure overload, or infusion of a fibrosispromoting neuroendocrine agonist cocktail 11 (FIG. 2) . Of note, during development and in other tissues, periostin is not exclusive to activated fibroblasts [59] [60] [61] . However, in adult, stressed cardiac ventricles, periostin is uniquely expressed by activated fibroblasts 11 . The Tcf21 genetic locus was also used to express a tamoxifenregulated Cre protein for lineage tracing, but this time to show that the overwhelming majority of tissueresident fibroblasts in the heart were of develop mental epicardial origin, and that this Creexpressing knockin allele was highly specific in the heart 11, 22 (FIG. 3) .
In support of this conclusion, Wt1
Cre−EGFP lineagetraced epicardial derivatives 41 also generated the vast majority of tissueresident fibroblasts in the heart after pressure overload 10 . Although Wt1 and Tbx18 are expressed in embryonic fibroblast progenitors, these genes are not expressed by most mature fibroblasts in the adult heart 62, 63 . However, Tcf21 continues to be expressed by adult cardiac fibroblasts 44 (FIG. 3) .
When investigating the endothelial origin of the ventricular septal and right ventricular fibroblasts, two groups have demonstrated that these fibroblast populations can produce ECM in response to pressure overload 10, 12 . Compared with the epicardialderived fibroblasts, gene expression and proliferation were similar in the two cell populations after injury. In con clusion, the tissueresident fibroblasts generated dur ing development are the primary source of the majority of activated fibroblasts after cardiac injury. Activated tissueresident fibroblasts also secrete factors that affect cardiac hypertrophy, but that are also likely to enhance the acute injury response and scar formation (reviewed previously 14, 64 ).
Human cardiac fibroblasts and fibrosis
Much of our knowledge about cardiac fibroblasts has been derived from studies using experimental animal models. Indeed, we know considerably less about the biology of human cardiac fibroblasts. Many studies on human cardiac fibroblasts have relied on primary in vitro culture techniques for their expansion and subsequent manipulation 6 . Other studies have examined fibroblasts using histological analysis of postmortem hearts and the use of αSMA to identify myofibroblasts 65 . One study using morphometric analysis demonstrated that mesen chymal cells, which include fibroblasts and peri cytes, comprise roughly 50% of the cells in the healthy human heart. This study used 14 C dating of cells from pathology free, postmortem hearts to calculate fibro blast longevity. The entire population of mesenchymal cells was estimated to be renewed about twice during a normal human lifespan and that numbers of these cells peak at age 30 years and then decline 66 .
Box 1 | How are fibroblasts activated?
In response to cardiac injury, both cytokine and neurohumoral factors are released and profound changes occur in the mechanical strain relationships within the ventricular wall (or septum), which together are thought to underlie fibroblast activation. A central cytokine involved in fibroblast activation, at least as defined in cultured fibroblasts, is transforming growth factor-β (TGFβ) 82 . TGFβ binds to and causes heterodimerization of TGFβ receptor 1 and 2 that in turn causes direct phosphorylation of the cytoplasmicallylocalized transcription factors SMAD2 and SMAD3, which then translocate to the nucleus in complex with SMAD4 to promote fibroblast differentiation-specific gene expression 83 . TGFβ receptor signalling as well as signalling from other neurohumoral factor receptors, including the angiotensin II receptor, also initiate fibroblast activation through engagement of mitogen-activated protein kinase (MAPK) effectors, such p38 (REFS 82, 83) . For example, activation of p38 in fibroblasts and other mesenchymal cell types induces collagen and smooth muscle α-actin (α-SMA) transcriptional activity as well as the appearance of α-SMA stress fibres [84] [85] [86] . A priority is to elucidate the entire molecular circuitry that regulates fibroblast activation, with the aim of identifying novel therapeutic approaches that might limit progressive cardiac fibrosis, as well as different stages of fibroblast differentiation in longstanding disease.
Although postmortem studies can provide useful information about fibroblast location and numbers, lack of definitive methods to identify cardiac fibroblasts in the human heart is still problematic. The alternative is to measure the products of fibroblast activity by either imaging or biochemical assays. The noninvasive visual ization of fibrotic scarring in the heart using MRI has become widespread, and has suggested that the pattern of scarring is dependent on the severity and type of insult 67 . A second method for monitoring emergent fibrosis is measurement of circulating factors 68 . Indeed, some biomarkers have been identified that can be used to indicate the extent of matrix deposition, although how this parameter might correlate with total fibroblast content in the heart is uncertain 14 . Given that ECM production or remodelling is a hallmark of fibroblast activation, a number of individ ual ECM, remodelling, and matricellular proteins have been proposed as markers for fibrosis, although some studies have not identified a reliable correlation between the amount of myocardial fibrosis and circulating colla gen components [69] [70] [71] . A combination of biomarkers pre dicting type I collagen crosslinking (ratio of circulating type I collagen to matrix metalloproteinase 1 [MMP1; also known as interstitial collagenase]) and deposition (procollagen type I peptide) has been examined. In this study, poor outcomes were associated with low type I collagen crosslinking and high type I collagen deposi tion in patients with hypertension and heart failure 72 . Another complication is that some presumed fibro sisindicating proteins can be secreted by inflammatory cells or possibly even other cell types present in the myo cardium during injury or longstanding fibrotic disease. Galectin 3, a proposed mediator of vascular fibrosis and inflammation, might be a more reliable biomarker for heart failure with associ ated fibrosis 73, 74 . The fibrosis associated microRNAs miR21 and miR19b have been suggested as circulating measures of cardiac fibrosis and heart failure 75, 76 . However, the current measures of fibroblast number and activity in the human heart, as well as total fibrotic content, remain unreliable and often indeterminate. Further molecular dissection of cardiac fibroblasts in animal models is likely to suggest alternative markers for application to human hearts to improve evaluation and tracking of ongoing dis ease, which is important for advances in treatment of fibrotic disease states with emerging therapeutic agents or strategies.
Unanswered questions
Using the newly generated and verified genetic lineage tracing mouse models discussed throughout this Review, researchers can now more reliably address fundamental concepts in fibroblast biology that remain unexplored. One very simple question is what happens to activated fibroblasts in a heart with injury resolution after MI, such as those cells within a stable scar after the acute healing process? The same question holds for the fate of activated fibroblasts in hearts when a pressure overload stimulus is removed. The two possibil ities are cellular apoptosis or reversion of the cell to its previ ous basal state. Studies have shown a dramatic expan sion of activated fibroblast numbers in the heart from tissue resident fibroblasts after MI injury or pressure overload 10, 11 . Kanisicak and colleagues also conducted a specific experiment in which fibroblasts were activated and lineage traced in hearts with the Postn mCrem mouse line during angiotensin II and phenylephrine infusion, followed by histological analysis 2 weeks after the infu sion was stopped so that the injury response regressed. The data showed that lineagetraced fibroblasts from the activation period were still present in the heart, and that they had a molecular programme more similar to a res ident fibroblast than an activated fibroblast 11 . However, total Postn mCrem lineagetraced fibroblast numbers were also substantially reduced, suggestive of cellular loss 11 . Many activated fibroblasts are, therefore, likely to undergo apoptosis after injury resolution in vivo, but some revert back to a baseline, 'resting' state. These con cepts need additional indepth analysis to understand the dynamics of fibroblast differentiation plasticity in vivo. Related to this concept, the reason why fully dif ferentiated, αSMAexpressing fibroblasts lack cellular stability and longevity remains intriguing, and suggests that they are not a truly differentiated cell type as classi cally defined, but are instead a 'supra physiological' state that requires continuous input for their maintenance. However, myofibroblasts resident in the scar of an The epicardial-derived fibroblasts emerge by the process of epithelial-to-mesenchymal transition of the epicardium at embryonic day E13.5 in the mouse, and constitute a majority of the ventricular and atrial cardiac fibroblasts. How the endothelial-derived cardiac fibroblasts arise during development is uncertain, but they contribute tissue-resident fibroblasts to regions of the right ventricle and of the ventricular septum. Studies have suggested a number of nonfibroblast cellular sources, such as endothelial cells, smooth muscle cells, monocytes, fibrocytes, and bone-marrow progenitors (designated with question marks), as the primary origin of newly generated activated fibroblasts and myofibroblasts in the heart after injury. However, recent studies with more highly refined genetic markers have not confirmed these results, and instead have shown that tissue-resident cardiac fibroblasts of developmental origin generate all the activated fibroblasts and myofibroblasts after injury. Pericytes have been reported to have fibroblast-like qualities in the heart when activated, but further work is needed to understand the potential role of these cells 51 . MIinjured heart might also remain indefin itely, given the ongoing stress and strain environment of the scar. If the contractile activity of myo fibroblasts is indeed important, their presence might help to maintain scar tension and stability over time
Another question is whether stable, intermediate states of fibroblast activation exist, or instead whether a scalable continuum of differentiation states exist that interpret the degree of cytokine and mechanical stimu lation. For example, one of the first events in fibroblast activation seems to be periostin expression, followed by αSMA expression 11 . One possible means of examin ing the question of lineage substates is singlecell RNA sequencing of activated fibroblasts isolated from the hearts of Postn mCrem lineagetraced mice 11 . These cells could be removed for analysis from the same region at different time points after injury, or from different regions of the heart so that cells in the scar that experi ence greater mechanical load could be compared with cells in the border zone with increased compliance. These geneexpression profiles could be clustered in an attempt to identify stable, intermediate differentiated states based on marker genes, or to build a model of a more fluid continuum of differentiated gene expression.
As discussed previously, fibroblasts are likely to be the primary mediators of the production of selected ECM proteins in the heart, as well as in most other tissues in vertebrate organisms. However, cardiomyocytes con tain a basal lamina of selected ECM proteins (especially fibronectin, but also α1 type I collagen and type VI colla gen) that form early in cardiac development before fibro blasts enter the heart. Moreover, lower organisms such Drosophila lack the fibroblast cell type despite having full capacity to mount a fibrotic response with collagen secretion by tissue parenchymal cells [77] [78] [79] [80] [81] . Therefore, whether fibroblasts are the only relevant source of colla gen and ECM production in the heart, either at baseline or with acute and chronic injury, remains to be tested. Indeed, mammalian cardiac myocytes can express and secrete collagens that could easily contribute to healing in the border areas of an MI 29, 30 . The capacity of activated fibroblasts to contract and remodel the heart in vivo through expression of smooth musclerelated contractile genes is also of unproven mechanistic importance. This unanswered question has direct implications in naming activated fibroblasts as myofibroblasts or possibly something else. Indeed, mitogenactivated protein kinaseactivated protein kinase 2 (Mapkapk2)deficient mice lack expression of important contractile genes in their activated fibroblasts during lung injury, even though these activated fibro blasts produce ECM even more abundantly than con trol fibroblasts replete in Mapkapk2 (REF. 7 ). In the future, it will be interesting to distinguish the ECMproducing functions of activated fibroblasts from their presumed contractile activity in the heart.
Conclusions
Many cellular functions have been attributed to car diac fibroblasts during homeostasis and cardiovascular remodelling, but the lack of a clear definition of a fibro blast might have led to inaccurate assumptions about this cell type. Our improved capacity to track fibro blasts in vivo is now providing exciting new avenues to understand and target maladaptive fibroblast activities in the heart, as well as potentially important adaptive or physiological functions. A stronger grasp of the identity and behaviour of cardiac fibroblasts and their different functional stages with defined molecular signatures will be critical in generating and evaluating new antifibrotic therapies for cardiovascular disease in humans, as well as designing new biomarkers to track fibrotic remodelling and evaluate treatment efficacy. Nature Reviews | Cardiology a b Figure 3 | Lineage tracing of resident cardiac fibroblasts. Hearts from adult Tcf21 mCrem mice containing a Cre-dependent ROSA26 TdT indicator that was induced with tamoxifen perinatally. Tissue-resident fibroblasts are labelled red. Mice were subjected to either a | a sham surgical procedure (no injury) or b | 6 weeks of a thoracic aortic constriction surgical procedure before harvesting. The images show that Tcf21-lineage tissueresident fibroblasts are uniformly distributed throughout the heart and that they expand with pressure-overload stimulation.
